Popular Articles

Deadly Leukemia Stem Cells Found And Eliminated By New Targeted Therapy
New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer. The study, published by Cell Press in the July 2nd issue of the journal Cell Stem Cell, describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of leukemia.

Diabetes UK Reaches Twitter Milestone
Diabetes UK has just reached the 1,000 follower mark on Twitter, the social networking and micro-blogging site that allows its users to send and receive each other"s updates, or "tweets".
News of the day
Health Officials Report 22 New H1N1 Swine Flu Cases In Mississippi
The Mississippi State Department of Health (MSDH) reports 22 new cases of H1N1 swine flu for last week, bringing the state"s total number of cases to 105. The new cases last week were in Lamar (6), Rankin (4), Covington (2), Madison (2), Chickasaw (1), Forrest (1), Harrison (1), Jackson (1), Lafayette (1), Monroe (1), Warren (1) and Winston (1) counties.
Endocrinology

Cook Medical Announces FDA Clearance For Advance(R) 35LP PTA Balloon Dilatation Catheter

Cook Medical has received clearance from the U.S. Food and Drug Administration (FDA) to market its newest balloon dilatation catheter, the Advance® 35LP. The device is intended for use in patients with lesions in the femoral, iliac and renal arteries and rounds out Cook"s complete line of low-profile PTA balloons. The Advance 35LP will play an integral part in Cook"s Leg Therapy Program, an initiative geared toward helping physicians address the anatomical challenges of treating Peripheral Vascular Disease (PVD) and deliver clinically effective interventional solutions to the patients who need them most. Commonly associated with diabetes, hypertension and coronary disease, PVD can result in amputation or death if left untreated. Few are aware of the minimally invasive treatment options available apart from amputation or surgical bypass, the latter of which is the current gold standard in treating this disease. The Advance line comprises three low-profile balloons (14LP, 18LP, 35LP) that range in size and composition to treat lesions in the peripheral arteries as well as obstructive lesions of native or synthetic arteriovenous dialysis fistulas. The Advance 35LP balloon, compatible with a .035-inch wire guide, is designed to address common above-the-knee blockages. The Advance 18LP, compatible with a .018-inch wire guide, is geared toward the femoral artery and popliteal region of the leg. The Advance 14LP, compatible with a .014-inch wire guide, is reserved for treatment of the most tortuous anatomies of the lower leg, including the popliteal and infrapopliteal arteries. Each balloon features a low crossing profile and small-sheath compatibility, which helps reduce the need for an invasive arterial entry and may shorten patient recovery time. Advanced thermal setting of the balloon folds improves rewrap and sheath pull-back, and a unique double-lumen shaft construction using optimized nylon-blend material reduces balloon inflation/deflation time and improves pushability while maintaining kink resistance. Cook Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):